Protagonist Therapeutics, Inc financial data

Symbol
PTGX on Nasdaq
Location
Newark, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1464% % 6.2%
Debt-to-equity 9% % -28%
Return On Equity 7% % -80%
Return On Assets 6% % -80%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62,515,666 shares 4.9%
Common Stock, Shares, Outstanding 62,447,102 shares 4.9%
Entity Public Float $2,000,000,000 USD 25%
Common Stock, Value, Issued $1,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 63,772,332 shares 3.2%
Weighted Average Number of Shares Outstanding, Diluted 63,772,332 shares 3.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $147,836,000 USD 12%
General and Administrative Expense $42,373,000 USD -0.44%
Operating Income (Loss) $19,008,000 USD -87%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $48,071,000 USD -72%
Income Tax Expense (Benefit) $2,162,000 USD -3%
Net Income (Loss) Attributable to Parent $45,909,000 USD -73%
Earnings Per Share, Basic 0 USD/shares -75%
Earnings Per Share, Diluted 0 USD/shares -76%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $113,713,000 USD -13%
Marketable Securities, Current $462,404,000 USD 37%
Other Assets, Current $191,000 USD -93%
Assets, Current $586,424,000 USD 23%
Property, Plant and Equipment, Net $4,100,000 USD 66%
Operating Lease, Right-of-Use Asset $8,174,000 USD -17%
Assets $701,688,000 USD 16%
Accounts Payable, Current $5,646,000 USD 85%
Accrued Liabilities, Current $22,868,000 USD 10%
Liabilities, Current $44,942,000 USD 0.82%
Operating Lease, Liability, Noncurrent $8,521,000 USD -22%
Liabilities $56,251,000 USD -22%
Accumulated Other Comprehensive Income (Loss), Net of Tax $525,000 USD -61%
Retained Earnings (Accumulated Deficit) $426,287,000 USD 9.7%
Stockholders' Equity Attributable to Parent $645,437,000 USD 21%
Liabilities and Equity $701,688,000 USD 16%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $125,363,000 USD
Net Cash Provided by (Used in) Financing Activities $11,443,000 USD 59%
Net Cash Provided by (Used in) Investing Activities $94,402,000 USD -1655%
Common Stock, Shares Authorized 180,000,000 shares 0%
Common Stock, Shares, Issued 62,447,102 shares 4.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $42,404,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $114,000,000 USD -13%
Deferred Tax Assets, Valuation Allowance $115,405,000 USD -31%
Deferred Tax Assets, Gross $117,510,000 USD -29%
Operating Lease, Liability $10,866,000 USD 852%
Payments to Acquire Property, Plant, and Equipment $545,000 USD 125%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $45,098,000 USD -74%
Lessee, Operating Lease, Liability, to be Paid $12,635,000 USD 989%
Property, Plant and Equipment, Gross $12,039,000 USD 28%
Operating Lease, Liability, Current $2,228,000 USD 4851%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,786,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $1,159,000 USD -0.09%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure -48%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,769,000 USD 9211%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,882,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $8,876,000 USD -87%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $30,573,000 USD 9.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,983,000 USD
Operating Lease, Payments $696,000 USD 3.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $239,000 USD 1.3%
Share-based Payment Arrangement, Expense $44,366,000 USD 27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%